Streetbeat News

Analyst Ratings

ROKU

Roku (NASDAQ:ROKU) has received mixed analyst ratings in the last quarter, with 5 bullish, 4 somewhat bullish, 6 indifferent, and 1 bearish. The average price target is $72.0, which is lower than the current price of $76.3075. The average price target has increased by 5.57% from the previous average of $68.20.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 7:00 pm

TS

Over the past 3 months, 5 analysts have published their opinion on Tenaris (NYSE:TS) stock. The company has an average price target of $41.96, representing a 3.92% decrease from the previous average price target of $43.67. The majority of the analysts are somewhat bullish on the stock.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 7:00 pm

MLTX

HC Wainwright has doubled the price target for MoonLake Immunotherapeutics (NASDAQ:MLTX) from $37 to $75 with a Buy rating, following positive results from its Phase 2 MIRA trial. The trial evaluated the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS). The analyst raised the probability of approval for sonelokimab in HS and PsA to 70% and reduced the discount rate to 11% from 13%. MoonLake is also reportedly considering a potential sale.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 6:39 pm

JANX

Janux Therapeutics Inc (NASDAQ:JANX) announced positive interim Phase 1 clinical data for its prostate cancer candidate, PSMA-TRACTr JANX007. The drug has been well tolerated with no dose-limiting toxicities and showed clinical activity. Concurrently, Janux priced an underwritten offering of over 4 million shares and pre-funded warrants, expecting to raise approximately $60 million. William Blair notes that Janux shares are currently undervalued based on the potential of the company’s TRACTr platform.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 6:36 pm

DIS

EXPE

IAC

NFLX

Barry Diller, chairman of IAC Inc and Expedia Group Inc, suggests that both executives and top-paid actors should take a 25% pay cut to narrow the pay gap in the movie industry. The Writers Guild of America and SAG-AFTRA are on strike, which could have devastating effects on the movie industry if not resolved by September 1. Wedbush analyst Alicia Reese believes the strikes could impact Netflix's Q3, while other studios with struggling streaming platforms could be hit harder. Disney CEO Bob Iger is concerned about the unrealistic expectations of the strikers.

Portfolio Pulse from Anthony Noto

July 17, 2023 | 6:33 pm

CHPT

TSLA

Oppenheimer analyst Colin Rusch reiterated an Outperform rating on ChargePoint Holdings Inc (CHPT) with a price target of $8.26. The analyst highlighted ChargePoint's key role in the EV charging landscape, its ability to service any OEM design, and its potential for positive operating leverage as channel revenues grow. The company is also well capitalized as it drives toward positive adjusted EBITDA in F2Y4.

Portfolio Pulse from Shivani Kumaresan

July 17, 2023 | 6:33 pm

NOW

A significant investor has taken a bearish stance on ServiceNow (NYSE:NOW), with 80% of recent trades indicating bearish expectations. The targeted price range for ServiceNow over the last 3 months is $490.0 to $700.0. The current price of NOW is up 2.19% at $593.08, with RSI indicators suggesting the stock may be approaching overbought. The next earnings are expected in 9 days.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 6:32 pm

VTGN

Vistagen Inc has revealed new data from a preclinical study of its itruvone nasal spray, a potential treatment for major depressive disorder. The study showed that a single intranasal administration of itruvone was undetectable in the brain and most other tissues, supporting the proposed mechanism of action of the spray. Vistagen recently reported that itruvone is now staged for potential Phase 2B clinical development in the U.S. VTGN shares are up 1.69% at $1.80 on the last check Monday.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 6:31 pm

MRK

A significant bullish stance has been taken on Merck & Co (NYSE:MRK) as evidenced by unusual options activity. The sentiment among these big-money traders is split between 53% bullish and 46% bearish. Whales have been targeting a price range from $85.0 to $115.0 for Merck & Co over the last 3 months. Morgan Stanley and HSBC have downgraded their actions to Equal-Weight and Hold respectively, with price targets of $109 and $123.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 6:16 pm

CVX

A significant bearish stance has been taken on Chevron (NYSE:CVX) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is 80% bearish and 20% bullish. The whales have been targeting a price range from $85.0 to $170.0 for Chevron over the last 3 months. Chevron's current price is $153.72, with next earnings expected in 11 days. Analysts from Raymond James, Mizuho, and Citigroup maintain their ratings on Chevron with price targets of $200, $205, and $170 respectively.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 6:16 pm